Destroyed our family : Mum s heartbreak after hospital blunder costs unborn son his life
17 Jan, 2021 07:39 PM
3 minutes to read
Sunny Alam and Sarah Hassan lost their baby boy due to a clinical error. Photo / Nine
Sunny Alam and Sarah Hassan lost their baby boy due to a clinical error. Photo / Nine
NZ Herald
An Australian mother has opened up about the heartbreaking moment her baby boy died during birth, due to a clinical mistake by staff.
Sarah Hassan was at Bunbury s St John of God Private Hospital in Perth on December 9 to give birth to her baby.
But a routine procedure turned deadly after she was mistakenly given 100 milligrams of morphine, more than 10 times the prescribed dose.
UNMC taking part in clinical trials for Novavax COVID-19 vaccine, seeking participants Share Updated: 11:04 PM CST Jan 14, 2021 Share Updated: 11:04 PM CST Jan 14, 2021
Hide Transcript
Show Transcript 1800 NEBRASKANS TO THE VIRUS. ROB: ANOTHER COMPANY HOPES TO ADD ITS VACCINE TO THE LIST OF LIFE-SAVING DOSES IN THE U.S. JULIE: THOSE CLINICAL TRIALS ARE UNDERWAY RIGHT NOW IN OMAHA. AS KETV NEWSWATCH 7’S JIM BRINKLOW REPORTS, A TOP EDUCATOR IS TAKING PART, AND HOPES YOU’LL DO THE SAME. DOSES FROM PFIZER AND MODERNA ARE ROLLING OUT, BUT THEY’RE NOT THE ONLY COMPANIES WORKING ON COVID-19 VACCINES. A UNMC DOCTOR SAYS THAT’S A GOOD THING, CONSIDERING 300 MILLION AMERICANS NEED THE SHOTS. I AM NOT SURE THAT WE CAN DO IT VERY FAST WITH ONLY TWO VACCINES AVAILABLE. DOCTOR DIANA FLORESCU IS IN THE INFECTIOUS DISEASE DEPARTMENT. SHE’S HELPING RESEARCH THE NOVAVAX VACCINE IN UNMC’S CLINICAL TRIALS. WE WANT TO REFLECT THE MOST VULERNABLE POP
Edison Investment Research Limited: ReNeuron Group (RENE): Continuing to Gain Clinical Data in Eye Disease
LONDON, UK / ACCESSWIRE / January 15, 2021 / After an eventful 2020, ReNeuron released updated 12-month Phase ll data in January on its lead human retinal progenitor cell (hRPC) project. This continues to show a consistent and robust, sustained average gain in visual acuity in retinitis pigmentosa (RP). A continuation study in nine patients using two million cells is underway with three- and six-month data due over H2 CY21 and the first three patients treated. This will facilitate partnering negotiations. A pivotal hRPC study may start in 2022. Deals are possible in CY21 on the exosome genetic drug delivery platform, which could be very valuable. The valuation remains at £190m with strong cash.
(1)
BEDMINSTER, N.J., Jan. 15, 2021 /PRNewswire/ Jubilant Therapeutics Inc., a biopharmaceutical company advancing small molecule modulators to address unmet medical needs in oncology and autoimmune diseases, today announced a collaboration with The Wistar Institute, an international leader in biomedical research, to evaluate the ability of Peptidyl Arginine Deiminase 4 (PAD4) inhibitors provided by Jubilant Therapeutics to block neutrophil extracellular trap (NET) formation in the context of COVID-19 related cytokine storms.
PAD4 is an enzyme that catalyzes conversion of arginine to citrulline in proteins, including histones and is highly expressed in neutrophils. Histone citrullination has been implicated in Neutrophil Extracellular Trap (NET) formation and accumulating evidence suggests that NETs may be linked to the severity of COVID-19, as their formation is a result of pro-inflammatory cytokine release syndrome (CRS), or cytokine storms, produced by the body s immune resp